Cefoxazole is a semi-synthetic, first-generation cephalosporin with bactericidal activity against penicillin-resistant strains of S. aureus and used in the treatment of bovine mastitis.

Cefivitril is a semi-synthetic cephalosporin with broad antibacterial activity against penicillin-resistant strains of S. aureus. Compared with the other cephalosporin, Cefivitril showed a better in vitro activity on gram pos. and gram neg. bacteria. Sensitivity tests were performed with 1007 bacterial strains to evaluate the in vitro activity of Cefivitril compared with that of cefuroxime and cephapirin. Compared with cefuroxiime and cephaprin, Cefivitril activity was significantly higher on Pasteurella and Salmonella, whereas no significant differences were detected for Streptococcus, Proteus, and Pseudomonas.

Cefempidone is a broad-spectrum cephalospolin antibiotic

Casokefamide is a synthetic peptide derived from the beta-casomorphin sequence, designed to increase the resistance to gastric proteases. . Casokefamide binds to both mu and delta-opioid receptors, while beta-casomorphins and its fragments are typical mu-opioid receptor agonists. Furthermore, casokefamide can affect gastric acid and pancreatic exocrine secretions and also gastrointestinal motility.

Cedefingol is a derivative of sphingosine, with potential antineoplastic activity. As a sphingosine derivative, cedefingol appears to inhibit protein kinase C (PKC), a kinase that plays an important role in tumorigenesis.

Triclacetamol is the trichloroacetyl derivative of paracetamol, one of the para-aminophenol series, and is a weak cyclooxygenase inhibitor with nonsteroidal anti-inflammatory drug (NSAID) analgesic and antipyretic activity. Also, it is an anti-inflammatory and uricosuric agent.

Pramiconazole is a novel azole with potent antifungal activity against yeasts, dermatophytes and many other fungal species. It is a new addition to the family of triazole antifungal agents that act by inhibiting fungal cell membrane ergosterol synthesis, thereby leading to increased cell permeability and destruction. In preclinical studies, pramiconazole exhibited similar or superior antifungal activity to ketoconazole and itraconazole, and selectively inhibited ergosterol synthesis with a broad spectrum activity. Pramiconazole was absorbed rapidly and had a long half-life, allowing for once-daily dosing. In phase I and II clinical trials, pramiconazole reduced the growth of Candida albicans, Malassezia globosa, Microsporum canis, Trichophyton mentagrophytes and Trichophyton rubrum, and was generally well tolerated. Pramiconazole is a well-tolerated and effective treatment for pityriasis versicolor.

Relacatib (SB-462795) is a potent and orally bioavailable small molecule inhibitor of cathepsin K that inhibits bone resorption. This has been shown in vitro in human tissue and in vivo in cynomolgus monkeys. The drug was developed for treatment in (postmenopausal) osteoporosis, osteoarthritis and potentially other bone disorders. Interactions with other drugs have been reported, and were subject of investigation of a phase I clinical trial (evaluating interactions of relacatib with ibuprofen, acetaminophen, and atorvastatin).

FLUDOXOPONE is an anticholesterolemic agent.